Protons substantially reduce kidney and bowel dose in prostate nodal reirradiation planning
In 15 prostate nodal recurrence cases, IMPT maintained target coverage while substantially reducing kidney, bowel and integral dose compared with VMAT.
In 15 prostate nodal recurrence cases, IMPT maintained target coverage while substantially reducing kidney, bowel and integral dose compared with VMAT.
In 50 patients, daily adaptive salvage SABR improved prostate fossa and nodal boost coverage while reducing bowel and rectal exposure.
Among 202 irradiated prostate cancer metastases, 54% developed local failure, while severe late radiation-attributed toxicity occurred after 2% of lesions.
Among 30 men with unfavorable-risk prostate cancer, single-fraction 24 Gy RT plus ADT produced 100% two-year biochemical control without grade ≥3 toxicity.
Among 702 prostate RT patients, an optimized language model reproduced manual NCCN risk groups in 96.2%, with most errors between intermediate-risk categories.
RapidPlan-guided Ethos plans reduced bladder and penile bulb doses and monitor units, but lowered prostate PTV coverage in 15 cases.
In ten anal cancer cases, IMPT reduced mean pelvic marrow dose from 24.3 to 12.3 Gy, but clinical toxicity reduction remains unproven.
Acute grade ≥2 urinary toxicity occurred in 64.7% of patients with periurethral calcifications versus 23.3% without them.
In 229 patients, late GI toxicity models achieved at best AUC 0.587, while GU prediction showed no reliable above-chance discrimination.
After 70 Gy(RBE) in 28 fractions, ten-year biochemical control was 78.5%, with grade ≥3 GI and GU toxicity in 5.2% and 3.1%.
In 62 patients receiving focal salvage HDR brachytherapy up to 30 Gy, no acute grade 3 toxicity occurred; genomic risk stratification showed promise.
MR-only prostate SABR reduced median penile bulb dose from 4.6 to 2.2 Gy, with lower observed urinary and sexual toxicity in nonrandomized cohorts.
After a second PSMA-guided metastasis-directed RT course, 50.2% of 177 oligorecurrent prostate cancer patients remained ADT-free at two years.
Removing lateral setup-shift scenarios reduced optimization time by 24 minutes across 16 prostate proton plans without significant changes in dosimetry or robust coverage.
Among 196 prostatectomy patients, pelvic nodal salvage RT was associated with improved biochemical control in margin-negative disease, while earlier treatment predicted better outcomes.